The Safety and Efficacy of Laparoscopic Surgical Staging and Debulking of Apparent Advanced Stage Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

被引:49
|
作者
Nezhat, Farr R. [1 ]
DeNoble, Shaghayegh M. [1 ]
Liu, Connie S. [2 ]
Cho, Jennifer E. [1 ]
Brown, Douglas N. [1 ]
Chuang, Linus [3 ]
Gretz, Herbert [3 ]
Saharia, Prakash [4 ]
机构
[1] Columbia Univ, Dept Obstet & Gynecol, Div Gynecol Oncol & Minimally Invas Surg, St Lukes Roosevelt Med Ctr, New York, NY 10019 USA
[2] NYU, Langone Med Ctr, Dept Obstet & Gynecol, New York, NY USA
[3] Mt Sinai Med Ctr, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol, New York, NY 10029 USA
[4] Winthrop Univ Hosp, Dept Gen Surg, Mineola, NY 11501 USA
关键词
Laparoscopy; Ovarian Cancer; Cytoreduction; IV EPITHELIAL OVARIAN; CYTOREDUCTIVE SURGERY; SURVIVAL; CARCINOMA; MANAGEMENT; LAPAROTOMY; IMPACT; RATES;
D O I
10.4293/108680810X12785289143990
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objectives: To describe our experience with laparoscopic primary or interval tumor debulking in patients with presumed advanced ovarian, fallopian tube, or peritoneal cancers. Methods: This is a retrospective analysis of a prospective case series. Women with presumed advanced (FIGO stage IIC or greater) ovarian, fallopian tube, or primary peritoneal cancers deemed appropriate candidates for laparoscopic debulking by the primary surgeon(s) were recruited. Results: The study comprised 32 patients who underwent laparoscopic evaluation. Seventeen underwent total laparoscopic primary or interval cytoreduction, with 88.2% optimal cytoreduction. Eleven underwent diagnostic laparoscopy and conversion to laparotomy for cytoreduction, with 72.7% optimal cytoreduction. Four patients had biopsies, limited cytoreduction, or both. In the laparoscopy group, 9 patients have no evidence of disease (NED), 6 are alive with disease (AWD), and 2 have died of disease (DOD), with mean follow-up time of 19.7 months. In the laparotomy group, 3 patients are NED, 5 are AWD, and 3 are DOD, with mean follow-up of 25.8 months. Estimated blood loss and length of hospital stay were less for the laparoscopy group (P=0.008 and P=0.03), while operating time and complication rates were not different. Median time to recurrence was 31.7 months for the laparoscopy group and 21.5 months for the laparotomy group (P=0.3). Conclusions: Laparoscopy can be used for diagnosis, triage, and debulking of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer and is technically feasible in a well-selected population.
引用
收藏
页码:155 / 168
页数:14
相关论文
共 50 条
  • [1] The safety and efficacy of laparoscopic surgical staging and debulking of apparent advanced-stage ovarian, fallopian tube, and primary peritoneal cancers.
    Nezhat, F.
    DeNoble, S. M.
    Liu, C. S.
    Cho, J. E.
    Brown, D. N.
    Chuang, L. T.
    Gretz, H.
    Saharia, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers
    Chi, DS
    Abu-Rustum, NR
    Sonoda, Y
    Ivy, J
    Rhee, E
    Moore, K
    Levine, DA
    Barakat, RR
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (05) : 1614 - 1619
  • [3] Safety and Efficacy of Video Laparoscopic Surgical Debulking of Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
    Nezhat, Farr R.
    Denoble, Shaghayegh M.
    Cho, Jennifer E.
    Brown, Douglas N.
    Soto, Enrique
    Chuang, Linus
    Gretz, Herbert
    Saharia, Prakash
    JSLS-JOURNAL OF THE SOCIETY OF LAPAROENDOSCOPIC SURGEONS, 2012, 16 (04) : 511 - 518
  • [4] Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
    Liu, Joyce F.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (5.5):
  • [5] Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer
    Li, Sue
    Manning-Geist, Beryl
    Gockley, Allison
    Ramos, Amanda
    Sisodia, Rachel C.
    Del Carmen, Marcela
    Growdon, Whitfield B.
    Horowitz, Neil
    Berkowitz, Ross
    Worley Jr, Michael
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (07) : 1052 - 1057
  • [6] Laparoscopic cytoreduction for primary advanced or recurrent ovarian, fallopian tube, and peritoneal malignancies
    Nezhat, F. R.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S60 - S61
  • [7] Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy
    Liu, Marisa C.
    Sutedja, Joyce
    Tewari, Krishnansu S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (05) : 475 - 480
  • [8] Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers
    E-I Braicu
    J Sehouli
    R Richter
    K Pietzner
    C Denkert
    C Fotopoulou
    British Journal of Cancer, 2011, 105 : 1818 - 1824
  • [9] Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers
    Braicu, E-I
    Sehouli, J.
    Richter, R.
    Pietzner, K.
    Denkert, C.
    Fotopoulou, C.
    BRITISH JOURNAL OF CANCER, 2011, 105 (12) : 1818 - 1824
  • [10] A multicenter prospective assessment of surgical findings associated with suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube and peritoneal cancer
    Suidan, R. S.
    Ramirez, P. T.
    Levine, D. A.
    Sonoda, Y.
    Abu-Rustum, N. R.
    Leitao, M. M.
    Zhou, Q.
    Amangurbanova, M. K.
    Levenback, C. F.
    Chi, D. S.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 40 - 40